These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 19189882)

  • 1. [Laboratory assessment of HDL heterogeneity and function].
    Movva R; Rader DJ
    Ann Biol Clin (Paris); 2009; 67(1):7-21. PubMed ID: 19189882
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Laboratory assessment of HDL heterogeneity and function.
    Movva R; Rader DJ
    Clin Chem; 2008 May; 54(5):788-800. PubMed ID: 18375481
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The rationale for using apoA-I as a clinical marker of cardiovascular risk.
    Barter PJ; Rye KA
    J Intern Med; 2006 May; 259(5):447-54. PubMed ID: 16629850
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Apolipoprotein A-I versus HDL cholesterol in the prediction of risk for myocardial infarction and stroke.
    Walldius G; Jungner I
    Curr Opin Cardiol; 2007 Jul; 22(4):359-67. PubMed ID: 17556890
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Should we take high-density lipoprotein cholesterol levels at face value?
    Leite JO; Fernandez ML
    Am J Cardiovasc Drugs; 2010; 10(1):1-3. PubMed ID: 20104929
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The role of the high-density lipoprotein (HDL) particle in atherogenesis and potential methods to increase HDL concentrations].
    Birjmohun RS; van der Steeg WA; Stroes ES; Kastelein JJ
    Ned Tijdschr Geneeskd; 2006 Oct; 150(41):2245-50. PubMed ID: 17076358
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is there a better marker of cardiovascular risk than LDL cholesterol? Apolipoproteins B and A-I--new risk factors and targets for therapy.
    Walldius G; Jungner I
    Nutr Metab Cardiovasc Dis; 2007 Oct; 17(8):565-71. PubMed ID: 17631989
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiatherogenic small, dense HDL--guardian angel of the arterial wall?
    Kontush A; Chapman MJ
    Nat Clin Pract Cardiovasc Med; 2006 Mar; 3(3):144-53. PubMed ID: 16505860
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Homocysteine increases the risk associated with hyperlipidaemia.
    Daly C; Fitzgerald AP; O'Callaghan P; Collins P; Cooney MT; Graham IM;
    Eur J Cardiovasc Prev Rehabil; 2009 Apr; 16(2):150-5. PubMed ID: 19276985
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Can cardiovascular events be prevented by raising HDL cholesterol?].
    Langslet G; Reikvam A
    Tidsskr Nor Laegeforen; 2008 Jun; 128(13):1519-23. PubMed ID: 18587459
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of cholesteryl ester transfer protein, peroxisome proliferator-activated receptor alpha, apolipoprotein E, and apolipoprotein A-I polymorphisms on high-density lipoprotein cholesterol, apolipoprotein A-I, lipoprotein A-I, and lipoprotein A-I:A-II concentrations: the Prospective Epidemiological Study of Myocardial Infarction study.
    Do HQ; Nazih H; Luc G; Arveiler D; Ferrières J; Evans A; Amouyel P; Cambien F; Ducimetière P; Bard JM
    Metabolism; 2009 Mar; 58(3):283-9. PubMed ID: 19217440
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The contribution of ApoB and ApoA1 measurements to cardiovascular risk assessment.
    Andrikoula M; McDowell IF
    Diabetes Obes Metab; 2008 Apr; 10(4):271-8. PubMed ID: 18333887
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HDL: still a target for new therapies?
    Nicholls SJ
    Curr Opin Investig Drugs; 2008 Sep; 9(9):950-6. PubMed ID: 18729001
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improvement of lipid profile is accompanied by atheroprotective alterations in high-density lipoprotein composition upon tumor necrosis factor blockade: a prospective cohort study in ankylosing spondylitis.
    van Eijk IC; de Vries MK; Levels JH; Peters MJ; Huizer EE; Dijkmans BA; van der Horst-Bruinsma IE; Hazenberg BP; van de Stadt RJ; Wolbink GJ; Nurmohamed MT
    Arthritis Rheum; 2009 May; 60(5):1324-30. PubMed ID: 19404933
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Introduction: Apolipoproteins and guidelines for prevention of cardiovascular disease.
    Faergeman O
    J Intern Med; 2006 May; 259(5):434-6. PubMed ID: 16629848
    [No Abstract]   [Full Text] [Related]  

  • 16. Speciation of human plasma high-density lipoprotein (HDL): HDL stability and apolipoprotein A-I partitioning.
    Pownall HJ; Hosken BD; Gillard BK; Higgins CL; Lin HY; Massey JB
    Biochemistry; 2007 Jun; 46(25):7449-59. PubMed ID: 17530866
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HDL-c is a powerful lipid predictor of cardiovascular diseases.
    Bruckert E; Hansel B
    Int J Clin Pract; 2007 Nov; 61(11):1905-13. PubMed ID: 17655681
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-density lipoproteins in the prevention of cardiovascular disease: changing the paradigm.
    Tuteja S; Rader DJ
    Clin Pharmacol Ther; 2014 Jul; 96(1):48-56. PubMed ID: 24713591
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluating the incremental benefits of raising high-density lipoprotein cholesterol levels during lipid therapy after adjustment for the reductions in other blood lipid levels.
    Grover SA; Kaouache M; Joseph L; Barter P; Davignon J
    Arch Intern Med; 2009 Oct; 169(19):1775-80. PubMed ID: 19858435
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of established hypolipidemic drugs on HDL concentration, subclass distribution, and function.
    Gomaraschi M; Adorni MP; Banach M; Bernini F; Franceschini G; Calabresi L
    Handb Exp Pharmacol; 2015; 224():593-615. PubMed ID: 25523003
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.